How often have we seen that caveat in news reports about FDA advisory committee meetings? But seldom is it as close as it was yesterday, whe...

We couldn't help but find a few interesting tidbits regarding the announcement that diagnostics maker Precision Therapeutics Inc. would ...

The UK’s National Institute of Clinical Excellence (NICE) is piloting a fee-for-service business that would see companies paying to receive ...

The speculation about the prospects for Lilly’s clot prevention drug prasugrel continues. The latest turn has been a rebound for Lilly, prom...

The weekend was not without some dealmaking action. More to come on Monday, for sure. But lets kick off the weekend roundup with a big biolo...

We were a bit taken aback by Lilly CEO Sidney Taurel’s editorial in the Wall Street Journal earlier this week recounting the damage done by ...

For some US home owners, this week brought bad news: the National Association of Realtors reports sales of previously owned homes hit their ...

Is there a way out of the woods for pharma companies hoping to win approval from the Food & Drug Administration for products for broad p...

Sanofi Aventis had already promised at their September R&D meeting that they wanted to increase the number of biologics in their pipeli...

In a short paper to appear in tomorrow’s Nature , scientists at Sirtris Pharmaceuticals describe the in vitro and in vivo data supporting ...